The agency issued priority vouchers for 3 experimental new drugs using psilocybin and methylone, amid Trump’s pro-psychedelics push. The Trump administration is putting America on the fast track to a ...

President Trump has signed an executive order to make certain psychedelic drugs more available to treat mental health conditions, such as depression and anxiety. He directed $50 million in federal ...

Shares of biotech firms and companies providing psychedelic-assisted therapy surged on Monday, after analysts applauded an ...

It's a big shift toward supporting psychedelic-based medicines for treatment-resistant depression, PTSD and substance use disorders, the FDA said.

The Food and Drug Administration says it will offer ultra-fast review to three psychedelic drugs being studied for hard-to-treat mental health conditions, including major depression.

The U.S. Food and Drug Administration may reportedly fast-track new drugs from pharmaceutical companies that “equalize” the cost of their medicines between the US and other countries. FDA Commissioner ...

The list of products receiving FDA Commissioner priority review vouchers will grow this week to include three psychedelic drugs.

Roche is the latest company trying to tap into the highly lucrative weight-loss drug market by fast-tracking its own candidates. The pharmaceutical giant said that its CT-388 drug is now entering the ...